Pharma Co. Secures $650M Strategic Financing

Research Report
  ()
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine.
Tags: Biotechnology / Pharmaceuticals

Pharma Stock Focuses on Successful Ensifentrine Launch

Research Report
  ()
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note.
Tags: Biotechnology / Pharmaceuticals

New COPD Drug Slated for Approval Decision This June

  ()
Ahead of the upcoming PDUFA date, several analysts recommend the biopharma behind this treatment as a Buy. Read on to learn why.
Tags: Biotechnology / Pharmaceuticals

Pharma Stock Nears FDA Approval

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval.
Tags: Biotechnology / Pharmaceuticals

Investor Conference Highlights New Strategic Directions for Addressing Opioid Crisis

  ()
Safe Supply Streaming has provided an update on Safety Strips, its recent acquisition. Read on for more about how this impacts the company's battle against the opioid crisis.
Tags: Healthcare Services

Breakthrough COPD Treatment Awaits FDA Approval, Promising Major Market Impact

  ()
Verona Pharma is poised for a pivotal breakthrough with its drug candidate, ensifentrine, potentially transforming COPD treatment pending an upcoming FDA decision. Read on for more.
Tags: Biotechnology / Pharmaceuticals

Critical Reforms Stuck in Congressional Gridlock

Contributed Opinion
  ()
McAlinden Research shares its thoughts on the current state of the cannabis market in light of recent legislative moves and two ETFs that may be impacted.
Tags: Cannabis

Medical School Renews Contract with Tech Co.

  ()
This move further validates the firm's Medical Education Suite. Discover why one analyst rates this healthcare-disrupting company as a Strong Buy.
Tags: Healthcare ServicesTechnology

Biotech Co. Positioned for Ensifentrine Approval, Analyst Says

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval.
Tags: Biotechnology / Pharmaceuticals

Pharma's Promising Path in COPD Treatment

  ()
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock.
Tags: Biotechnology / Pharmaceuticals

PDUFA Date Coming Up for U.K. Biopharma

Research Report
  ()
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
Tags: Biotechnology / Pharmaceuticals

Biopharma's New Drug for COPD Likely to be Approved

Research Report
  ()
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

AI Healthcare Stock Has Bullish Setup, Expert Says

Contributed Opinion
  ()
Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy.
Tags: Life Sciences Tools & Diagnostics

New AI Solutions Set To Transform Medical Education and Clinical Practice

  ()
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).
Tags: Healthcare Services

Analyst Says Pharma Co. Has No True Competitor

Research Report
  ()
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
Tags: Biotechnology / Pharmaceuticals

LA Biotech's Lower Revenue Will Be Short Lived

Research Report
  ()
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Healthcare Co. Welcomes Possible AI Funding Effort in Canada

  ()
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.
Tags: Life Sciences Tools & DiagnosticsMedical DevicesHealthcare ServicesTechnology

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out

  ()
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
Tags: Biotechnology / PharmaceuticalsGoldOil & Gas - Exploration & ProductionSilver

Co. Adding 500 Patients to Its Mental Health Care Platform

  ()
This Canada-based health care technology firm is profitable and growing. Learn more about it here.
Tags: Healthcare Services

Analyst Encouraged by ON Gov's Decision To Sustain Fees

Research Report
  ()
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.
Tags: Healthcare Services

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock

  ()
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
Tags:  Biotechnology / Pharmaceuticals